In an observational study, we examined the association between treatment with various classes of antihypertensive agents and 3-year changes in serum creatinine in 1296 older adults with treated hypertension and without prior renal disease (mean age 72.2 years; 60% female; 30% diabetic; 42% with cardiovascular disease (CVD)) from the Cardiovascular Health Study. Baseline antihypertensive medications included thiazides (HCT), ␤-adrenergic blockers, angiotensin converting enzyme inhibitors (ACE-I), calcium channel blockers (CCB), vasodilators (VAS), HCT ؉ BB, HCT ؉ ACE-I, HCT ؉ CCB, HCT ؉ VAS, loop diuretics (LOOP), and other combinations.
T he role of the kidneys in the control of blood pressure is well established, as is the role of high blood pressure in affecting renal function and inflicting renal injury in adults, [1] [2] [3] [4] [5] especially among older adults. 6 Over half of US adults aged 60 years and older are hypertensive and half of them are being treated with an antihypertensive agent. 7 Although observational data on treatment effects in the nonelderly suggest no change in renal function, 8, 9 one randomized trial suggested that, compared with placebo, pharmaceutical treatment had adverse effects on renal function in the elderly. 10 The extent to which major classes of hypertensive agents may differentially affect renal function in the elderly is unknown. No large-scale clinical trials comparing these agents have been completed, 11, 12 and data are likely to remain unavailable until 2002 when the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attacks Trial (ALLHAT) reaches its conclusion. 11 Those clinical trials of hypertension treatment in the elderly that have compared up to three treatments have not published data on renal function, [13] [14] and the one that has published compared treatment with placebo. 15 The Treatment of Mild Hypertension Study, 16 a clinical trial in middle-aged adults (mean age: 54.8 years), compared changes in serum creatinine over an average of 4.4 years among subjects randomized to acebutolol, amlodipine, chlorthalidone, doxazosin, enalapril, or placebo and found that only acebutolol use was associated with statistically significant changes over time in which the decrease in serum creatinine among acebutolol users was significantly smaller (Ϫ0.01 mg/dL) than among users of all other treatments (Ϫ0.05 mg/dL).
The public health implications of increases in population serum creatinine levels, even among low-risk individuals, may be great and might potentially increase further the already growing rate of end-stage renal disease, 17 ,18 a costly and potentially avoidable outcome. Thus, evidence of acceleration or retardation of the loss of renal function associated with antihypertensive therapies in the elderly would have widespread public health importance.
In the present study, we used data from a cohort of adults aged 65 years and older to examine the association of treatment with various classes of antihypertensive agents and changes in serum creatinine over 3 years of follow-up. Based on the National High Blood Pressure Education Program Working Group Report on hypertension and chronic renal failure, we hypothesized that most treatment regimens would not be associated with changes in serum creatinine when compared with thiazide diuretic use with the possible exception of angiotensin converting enzyme inhibitors, which may show a beneficial effect.
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METHODS
Setting
The Cardiovascular Health Study (CHS) is a population-based, longitudinal study of coronary heart disease and stroke in community-dwelling adults aged 65 years or older. 20 The original cohort consisted of 5201 participants who were sampled from Medicare eligibility lists in four communities: Forsyth County, North Carolina; Sacramento County, California; Washington County, Maryland; and Pittsburgh, Pennsylvania. Comprehensive examinations that consisted of extensive physical and laboratory measurements were conducted at baseline from 1989 to 1990 and at 3-year follow-up from 1992 to 1993.
Subjects CHS participants who reported no history of renal disease at baseline, for whom baseline and follow-up data on serum creatinine were available, and for whom baseline medication and hypertension-status data were available were eligible for analyses.
Groups of untreated hypertensives (positive hypertension history without therapy), normotensives (negative hypertension history without therapy), and normotensives treated with antihypertensive agents for other indications (negative hypertension history with therapy) were identified and were used to describe the cohort from which treated hypertensives were drawn. Three groups of treated hypertensives were formed. The first group was defined as individuals who reported a diagnosis of high blood pressure on a baseline medical history questionnaire and who were using antihypertensive therapy upon entry into the study (see Measures section). This group comprised all treated hypertensives, some of whom may have switched treatment therapies over time. The second group was a subset of the first group and contained only those who were using the same therapy at baseline and at 3-year follow-up. This group comprised continuous users of the same antihypertensive treatment. The third group, not a subset of the first group, was defined as individuals who were not using antihypertensive therapy upon study entry but who, at the end of 3 years of follow-up, were using antihypertensive therapy and reported a positive history of hypertension. This group comprised starters of antihypertensive treatment.
Measures Venipuncture was performed after a 12-h fast at both baseline and follow-up examinations. Blood was stored at Ϫ70°C until it was shipped on dry ice from each of the four sites to a central blood analysis laboratory. Creatinine and other blood chemistry analyses were performed on a Kodak Ektachem 700 Analyzer (Kodak Corp., Rochester, NY).
Medication data were collected by medication inventories. At baseline, study interviewers visited participants in their homes and asked to see all prescription medications that they had taken in the previous 2 weeks. At follow-up, participants brought to the clinic examination all prescription medications they had taken in the previous 2 weeks. Information on drug name, dose, and frequency of use were recorded. 21 Antihypertensive medications were categorized into 11 mutually exclusive therapies at baseline and at follow-up: thiazide-like diuretics alone (HCT, reference group), ␤-adrenergic blockers alone (BB), calcium channel blockers alone (CCB), angiotensin converting enzyme inhibitors alone (ACE-I), non-ACE-I, non-CCB vasodilators alone (VAS, including primarily hydralazine, reserpine, clonidine, and ␣-adrenergic blockers), HCT ϩ BB, HCT ϩ ACE-I, HCT ϩ CCB, HCT ϩ VAS, loop diuretic use alone or in combination with any other drugs (LOOP), and any other combination of two or more drugs excluding loop diuretics (OTHER).
Participants were contacted semiannually and were asked if they had been hospitalized in the past 6 months. Additionally, Medicare files were searched to identify hospitalizations that may have been missed. In-hospital renal dialysis events were identified by procedure code 39.95, and cases of renal failure and disease were identified by ICD-9 codes 403, 584-589, 958.5, 997.5 in hospitalization discharge records.
Statistical Analyses
Unadjusted mean baseline and 3-year changes in serum creatinine are reported for treated and untreated normotensive and hypertensive participants as well as for participants in each antihypertensive therapy group. Student's t-tests were performed on each difference to determine whether 3-year changes were statistically different from zero.
For participants with treated hypertension, multivariate linear regression modeling was used to estimate and compare the mean 3-year serum creatinine changes among the 11 antihypertensive therapies while adjusting for baseline serum creatinine levels. Users of HCT, the most frequently used therapy, were the reference group. The regression model was applied to each of the three groups of treated hypertensives.
Multivariate analyses were adjusted for age, sex, and baseline measures of the following variables: serum creatinine, height, weight, smoking, glucose intolerance (fasting glucose Ͻ 140 mg/dL and 2-h postglucose load between 140 and 199 mg/dL), diabetes (defined by fasting glucose levels Ն 140 mg/dL, 2-h post-glucose load Ն 200 mg/dL, reported history of diabetes, use of insulin, or use of oral hypoglycemic medication), carotid intima-media thickness, cardiovascular disease (history of myocardial infarction, angina pectoris, claudication, congestive heart failure, stroke, or transient ischemic attack), and allopurinol, phenytoin, cimetidine, and nonsteroidal antiinflammatory drug use. Additionally, analyses were adjusted for 3-year follow-up measures of these four drugs.
RESULTS
Of the 5201 participants, 3971 (76.4%) had data available on baseline hypertension status, medication data, and both baseline and follow-up serum creatinine measures. We excluded 85 (2.1%) who reported a history of renal disease at baseline examination (mean serum creatinine 1.13 mg/dL). Among the remaining 3886 participants, 1296 (33.3%) had treated hypertension, 377 (9.7%) reported a history of hypertension but were not currently receiving pharmaceutical treatment, 338 (8.7%) were normotensive and using potential antihypertensive agents for other indications, and 1875 (48.3%) were untreated and normotensive. Table  1 lists baseline and 3-year follow-up change in serum creatinine measures among these four groups. Untreated hypertensives, who were not included in further analyses, were younger, more likely to be nondiabetic and male, and had higher systolic and diastolic blood pressure than did treated hypertensives. Sixtyone percent remained untreated after 3 years of follow-up. Table 2 presents selected baseline characteristics of users of various antihypertensive therapies among treated hypertensive participants. Women were more likely to be using HCT, alone or in combination with CCB or VAS, and loop diuretics. Although diabetics were more likely to be using HCT ϩ VAS combination and loop diuretics, the proportion of users who were diabetic for other drugs (with the exception of HCT ϩ CCB) was remarkably similar. Users of ACE inhibitors had a shorter duration of drug-treated hypertension than did participants using other therapies, and users of loop diuretics were in poorest health according to self-report. Table 3 presents the percentage of participants in each of five levels of baseline blood pressure readings according to baseline antihypertensive therapy. Blood pressure was classified according to the higher reading of either diastolic or systolic. Systolic pressures classified nearly 80% of the participants. Systolic blood pressures Ͼ 139 mm Hg or diastolic pressures Ͼ 89 mm Hg ranged from 34.1% (HCT ϩ ACE-I) to 58.7% (CCB) of participants. Table 4 presents unadjusted mean baseline and 3-year changes in serum creatinine measures and 95% confidence intervals for all treated hypertensive patients and for each of the 11 mutually exclusive therapies according to baseline antihypertensive drug use. For treated hypertensives the overall change was ϩ0.03 mg/dL (95% confidence interval (CI): 0.02, 0.04). Most of the therapy-specific changes were small, and few were statistically significant: HCT: ϩ0.02 mg/dL (95% CI: 0.00, 0.04), ACE-I: ϩ0.04 mg/dL (95% CI: 0.01, 0.08), CCB: ϩ0.04 mg/dL (95% CI: 0.01, 0.07), and LOOP: ϩ0.06 mg/dL (95% CI: 0.02, 0.10).
At the third year of follow-up, adverse renal outcomes were uncommon among participants: one had a hospitalization for renal dialysis (VAS user), and 59 (4.6%) had hospitalizations for renal failure (without mention of dialysis) ( Table 4) . Table 5 presents mean 3-year changes in serum creatinine associated with baseline use of various classes of antihypertensive drugs relative to HCT (absolute change ϩ0.02 mg/dL). Due to missing covariate data, 28 subjects were excluded so that 1268 participants were available for multivariate analyses. Among all subjects combined, only one We restricted the second analysis to the 721 participants who used the same antihypertensive therapy at both baseline and 3-year follow-up. These participants were considered continuous users of specific antihypertensive therapies. Complete data on all covariates were available for 706 of the participants (97.9%). Among continuous users (Table  6) , there were minimal 3-year changes in serum creatinine. Compared with HCT use (absolute change ϩ0.01 mg/dL), LOOP use was associated with small but significant increases in serum creatinine: ϩ0.05 mg/dL (95% CI: 0.02, 0.07). Among women, ACE-I was associated with a significant serum creatinine increase (ϩ0.07 mg/dL; 95% CI: 0.03, 0.10), as was HCT ϩ BB among nondiabetics compared with users of HCT alone (ϩ0.10 mg/dL; 95% CI: 0.06, 0.13). Table 7 presents mean 3-year serum creatinine changes for those patients who were not treated at baseline with antihypertensive medication but who, at 3-year follow-up, both reported a history of hypertension and received antihypertensive treatment. Antihypertensive therapies are those used at 3-year follow-up. Overall, no treatments were associated with statistically significant changes in serum creatinine compared with that in HCT users. These recent starters of antihypertensive therapy were further divided into those with and those without a self-reported history of hypertension at baseline. Significant associations were only found among users of HCT ϩ ACE-I who reported a history of hypertension, but the number in this group was small (n ϭ 3).
In addition to the primary analyses presented for 1296 participants, secondary analyses were conducted on 1203 (92.8%) participants who had baseline serum creatinine of 1.5 mg/dL or less, among 1156 (89.2%) participants for whom there was information on length of hypertension treatment, and among 1229 (94.8%) who had baseline diastolic blood pressure readings Ͻ 110 mm Hg and systolic readings Ͻ 180 mm Hg. In all analyses associations between serum creatinine measures and antihypertensive drug therapies were small and similar to results in the primary analyses. Only associations among HCT ϩ VAS use in the full cohort and continuous HCT ϩ BB use in nondiabetics persisted throughout secondary analyses. In other exploratory analyses, CCB, HCT ϩ CCB, VAS, HCT ϩ VAS, and OTHER therapy groups were subdivided. Apart from the VAS differences mentioned earlier, dihydropyridine and nondihydropyridine subgroups of CCB, and two-drug and three-drug subgroups of OTHER were not associated with significant 3-year creatinine changes.
DISCUSSION
Our analyses suggest that among older adults without prior renal disease, 3-year mean changes in serum creatinine were small for all subjects and they did not vary significantly among the most commonly used antihypertensive therapies. Most differential changes among therapies were within the play of chance and, among those that were not, the magnitude of the change was small. The association of thiazide diuretics plus vasodilators with serum creatinine was not present among continuous users. The hydralazine findings were derived from exploratory analyses but merit further exploration in other data sets. The loop diuretic findings were not surprising given that they are not standard therapies for hypertension treatment and are clinically used preferentially in patients who do not respond to thiazides and may have decreased renal function. Combination thiazide and ␤-blocker use was associated with elevated serum creatinine compared with thiazide alone among nondiabetics, although use of ␤-blockers alone was not. In general, neither the participant's sex, diabetic status, nor cardiovascular disease status significantly influenced the findings. In this study of renal function in elderly subjects, the new agents such as ACE inhibitors, which have had variable success at improving renal function in randomized trials, 18, [22] [23] [24] and calcium channel blockers did not appear to be associated with any differential rate of change in renal function compared with older therapies, namely thiazide diuretics and ␤-blockers.
Several points need to be made concerning our study and its findings. First, serum creatinine measures have limited sensitivity for evaluating renal function: up to 50% of the renal function can be lost before serum creatinine rises above normal levels. 25, 26 No other measures of kidney function were available and adverse renal outcomes were too rare to warrant comparisons between treatment therapies. Although the size of the CHS study does not remedy these deficits, it does offer the advantage of increased power to detect relatively small serum creatinine changes. Although we know that most participants had been receiving antihypertensive medications for an average of 12.7 years, no data were available on the type of antihypertensive medication used before baseline examination. Three years of observation may be the minimum follow-up interval necessary to detect declining renal function 27 and is within range of the 3 to 5 year follow-up in randomized trials. 6, 15, 18 We also know that the use of various antihypertensive agents has changed rather dramatically over time. 28, 29 In the full hypertensive cohort (n ϭ 1296), 44.4% of participants (n ϭ 575) changed their antihypertensive drug regimen during the study. Nearly half (46%) were still using two drugs at follow-up; a minority (17%) went from monotherapy using one agent to monotherapy using another agent. The mean serum creatinine level was higher among participants who changed therapy (1.10 mg/dL) compared with the continuous users who did not (1.06 mg/dL) suggesting that elevated creatinine measures may have been a consideration in switching. Among therapy changers, there was no evidence that creatinine changes over time differed by therapy type although it is difficult to attribute changes in serum creatinine to any particular class of drug in these subjects.
The analysis excluded participants who were without a serum creatinine measure at 3-year follow-up.
Although missing follow-up data are strongly associated with participant illness and disability, it is unlikely that renal functional impairment due to differential effects of various classes of antihypertensive drugs was strong enough to introduce selection bias. Moreover, of the 414 treated hypertensive participants with baseline serum measures who did not have follow-up serum creatinine measurements, two of the 160 deaths at the third year of follow-up (1.3%) mentioned the kidneys on the death certificate as either being involved in or underlying the cause of death, and 20 of the 254 who were not dead (7.9%) were hospitalized with a discharge diagnosis of renal failure.
Laboratory drift in the measure of serum creatinine presumably does not account for observed changes over time, as new cohort members who were enrolled at 3-year follow-up (not included in these analyses) had creatinine values that did not differ from race-matched cohort members enrolled at baseline.
This study had 80% power (two-sided ␣ ϭ 0.05) to detect the following minimum effect sizes for differences in 3-year changes between HCT users and other users of antihypertensive therapy: Յ 0.05 mg/dL for BB and CCB users; Յ 0.10 mg/dL for ACE-I, VAS, HCT ϩ BB, HCT ϩ ACE-I, HCT ϩ CCB, OTHER, and LOOP users; and Յ 0.18 for HCT ϩ VAS users. Additionally, due to the large number of statistical com- parisons made among subpopulations, the possibility of finding spurious but statistically significant associations by chance is not negligible. For this reason, those associations with P values Ͻ .01 are noted on the tables. Lastly, this is an observational study where treatments were not randomly assigned to individuals. The absence or presence of certain associations may still be due to uncontrolled confounding even though we adjusted for multiple potential confounding factors.
In conclusion, our findings did not reveal associations between specific antihypertensive treatments and changes in serum creatinine in older adults without renal disease. These data also suggest that serum creatinine levels increase minimally over time in pharmaceutically treated elderly hypertensives and that any differential drug effect may be small and of minor consideration to clinicians when choosing among hypertensive therapies.
